By:
On:
In: Quick Answer
With: 0 Comments

After completion of 1 year trastuzumab in the adjuvant setting, LVEF monitoring every 6 months for at least 2 years is recommended. If trastuzumab is withheld for significant LV cardiac dysfunction, cardiac monitoring should occur monthly. What is Herceptin Hylecta? Herceptin Hylecta is a combination of trastuzumab, a HER2/neu receptorRead More →